---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-034547"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2023-10-18T23:59:59+00:00"
generated_at: "2026-06-09T21:48:19.871330+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# X4 Pharmaceuticals appoints industry veteran R. Keith Woods to Board of Directors

## Summary
- Woods appointed as independent Class II director effective Oct 16, 2023, term through 2025 annual meeting.
- He brings 30+ years life science experience, most recently COO of argenx, leading rare disease global launch.
- Received initial equity award of 90,000 RSUs vesting equally over 3 years; accelerated on change of control.
- No family relationships or material interests with directors/officers; standard indemnification agreement entered.
- Appointment follows recent U.S. regulatory submission of X4's first drug candidate (mavorixafor) for WHIM syndrome.

## SEC filing metadata
- accession: 0001628280-23-034547
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2023-10-18T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828023034547/0001628280-23-034547-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828023034547/xfor-20231016.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-034547
- JSON: https://secwatch.observer/filing/0001628280-23-034547.json
- Plain text: https://secwatch.observer/filing/0001628280-23-034547.txt

## Key facts
- Executive change
  Keith Woods was appointed as Director at X4 Pharmaceuticals, Inc.
  - Action: appointed
  - Role: Director
  source text: On October 16, 2023, the Board of Directors (the “Board”) of X4 Pharmaceuticals, Inc. (the “Company”) appointed Keith Woods as a member of the Company’s Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501697/000162828023034547/0001628280-23-034547-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.